MetaCap

Generate Biomedicines Inc. (GENB)

NASDAQ: GENBHealth CareBiotechnology: Pharmaceutical PreparationsUSD

9.54-0.83 (-8.00%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

GENB stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$2.49
52-week range
9.40 – 22.67
Day range
9.40 – 10.58
Volume / Avg
967.20K / 1.24M
Beta
—

52-week range

$9.40$22.67

GENB stock today

On Nov 20, GENB ended the session at $9.54, shedding $0.83 (8.00%), versus the S&P 500's 3.70% decline. At this level, GENB sits near the bottom of its 52-week range of $9.40 to $22.67: 57.9% below the high, set on Aug 25, 2026 and 1.5% above the low. Generate Biomedicines has posted a net loss over the last twelve months (EPS of -$2.49), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Generate Biomedicines

Company profile

Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Michael T. Nally M.B.A.
Headquarters
Somerville, MA
Employees
312
IPO year
2026

Analyst forecast

Forecast

Consensus (5 analysts)

strong_buy

Avg. price target

$27.00+183.02%

  • Strong buy 2
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $22.00High $30.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.68 vs $-0.50
Surprise
-36.00%

GENB news

All GENB news

Generate Biomedicines peers

Health Care sector
GENB peer companies
CompanyPrice% ChgMarket capCompare
SLNSilence Therapeutics Plc American Depository Share19.810.00%$1.23Bvs GENB
OCULOcular Therapeutix Inc.5.57-4.95%$1.23Bvs GENB
MNKDMannKind Corporation3.85-2.53%$1.24Bvs GENB
MLYSMineralys Therapeutics Inc.13.66-3.53%$1.21Bvs GENB
LBRXLB Pharmaceuticals Inc38.85-2.97%$1.26Bvs GENB
AMPHAmphastar Pharmaceuticals Inc.28.25+0.50%$1.20Bvs GENB
GHRSGH Research PLC17.53-5.55%$1.20Bvs GENB
AVLNAvalyn Pharma Inc.28.40-1.05%$1.26Bvs GENB

Indexes, lists and sector

Generate Biomedicines stock FAQ

What is Generate Biomedicines's stock price today?

GENB last traded at $9.54 as of Nov 20, 4:00 PM EST, down 8.00% on the day. Prices are delayed at least 15 minutes.

Who is Generate Biomedicines's CEO?

Mr. Michael T. Nally M.B.A. is the chief executive officer of Generate Biomedicines Inc., which has about 312 employees.

What is the GENB 52-week high?

The 52-week high for GENB is $22.67 and the 52-week low is $9.40. The stock is currently 57.9% below its high.

Compare GENB